Stock INDP INDAPTUS THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Indaptus Therapeutics, Inc.

Equities

INDP

US45339J1051

Delayed Nasdaq
Other stock markets
 12:54:48 2024-04-30 pm EDT 		5-day change 1st Jan Change
2.142 USD +0.95% Intraday chart for Indaptus Therapeutics, Inc. -13.98% +21.70%
Mar. 14 Top Premarket Gainers MT
Mar. 13 Indaptus Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Indaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual Meeting
AQ
Indaptus Therapeutics : April 2024 April 2024 Investor Presentation
PU
Indaptus Therapeutics to Present at the MedInvest Biotech and Pharma Investor Conference
AQ
Indaptus Therapeutics Previews Positive Mechanism of Action Data to be Presented at the American Association for Cancer Research Annual Meeting
AQ
Indaptus Therapeutics to Participate in Tribe Public Webinar On Wednesday, March 20, 2024
AQ
Top Premarket Gainers
MT
Indaptus Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Indaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
AQ
Top Midday Gainers
MT
Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose Cohort
AQ
Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial
CI
Indaptus Therapeutics to Present at the 2024 BIO CEO & Investor Conference
AQ
Indaptus Therapeutics Expands Digital Presence with Launch of Social Media Channels
AQ
Indaptus Therapeutics Expands Digital Presence with Launch of Social Media Channels
CI
European Patent Office Approves Key Patent for Indaptus Therapeutics’ Platform Technology
AQ
Indaptus Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Indaptus Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
AQ
Indaptus Therapeutics’ Decoy20 Demonstrated a Broad Immune Response of More than Fifty Cytokines and Chemokines in Patients Following a Single Dose in First Cohort of Ongoing Phase 1 Study
AQ
Indaptus Therapeutics, Inc. Announces Interim Data from the First Cohort of Four Patients in the Phase 1 INDP-D101 Trial of Its Lead Compound, Decoy20
CI
Indaptus Therapeutics, Inc. Releases Interim Data from the First Cohort of Four Patients in its Phase 1 INDP-D101 Trial of Its Lead Compound, Decoy20
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. INDP Stock
  4. News Indaptus Therapeutics, Inc.